Project Grant HT94252410710
Award Date 9/15/24
Completion Date 9/14/27
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,361 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 1, 2026 through April 30, 2031. This award supports research targeting Ring Finger Protein 2 (RNF2) to synergize with oncolytic immunovirotherapy for inducing anti-cancer immunity in...
- Federal Project Grant Award Summary Mayo Clinic Jacksonville received a $161,300 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on August 24, 2026, with completion anticipated by August 23, 2027. The grant supports research to decode and target the molecular mechanisms of TRAF7 and KLF4 driver mutations in meningioma, the most common...
- Federal Project Grant Summary: Investigation of a Novel Molecular Driver of Schwannoma Nerve Sheath Tumors The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $1,151,209 to The Leland Stanford Junior University (awarded July 15, 2025; completion date June 30, 2030) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This research initiative investigates SOX10 indel mutations as a novel...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco $681,070 under the Cancer Treatment Research program (CFDA 93.395) on June 4, 2026, for a five-year project period concluding May 31, 2031. The research initiative investigates the functional relationship between NF2 and NF1 tumor suppressor genes in peripheral nervous system (PNS) tumors, specifically malignant peripheral nerve sheath tumors (MPNSTs),...
- Federal Cooperative Agreement Award Summary Mayo Clinic received a $688,661 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded June 9, 2026, with a completion date of May 31, 2031. This award supports research focused on prospective detection and monitoring of NF1 (Neurofibromatosis Type 1) peripheral nerve sheath tumors using cell-free DNA analysis. The research will develop integrative multi-omic...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $638,697 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 15, 2025, through June 30, 2030. The award supports research investigating the role of SMARCA5, an ISWI (Imitation Switch/Chromatin Remodeling)...
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...
- The University of Manchester received a $396,778 Project Grant award from the Defense Health Agency to model the risk of radiation-associated malignant progression in familial Neurofibromatosis type 2 (NF2) using machine learning approaches. The award was made under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve military and public health care through innovative solutions for battlefield medicine and other areas. Over a...
- The National Cancer Institute (NCI) awarded a $156,080 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the University of California, Berkeley, effective January 1, 2026, through December 31, 2028. This award supports the development of novel Anaplastic Lymphoma Kinase (ALK) targeting therapies through the expansion of targeted protein degradation approaches. The research addresses the critical challenge of resistance to tyrosine kinase inhibitors (TKIs) in ALK-driven...
TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS
Posted 6/26/24
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 6/26/24 |